$BEAT
*HeartBeam (BEAT) flat +0.12% to +0.92% at $0.81-$0.82, trying to base above $0.80 support.*
Price: *$0.81-$0.84* | Market cap: *$46.6M-$50.3M* | 52-week range: *$0.54-$4.00*
๐ *Move*: +0.12% to +0.92% today. Down -3.4% yesterday, -6.7% past 5 days, -65.7% YTD. Still -79% from $4.00 high. Analyst avg target $4.33 implies +433% upside.
๐ท๏ธ *Catalyst*: Q1 2026 results: $4.7M net loss but began first US commercial partnerships + raised $11.5M in April. New JACC peer-reviewed study shows portable ECG can identify heart attack risk at home vs 12-lead. Zacks upgraded to Buy #2.
โ ๏ธ *Technicals*: Trading below all MAs: 5-day $0.87, 20-day $0.91, 200-day $1.46. RSI 38-39 = oversold. Key support $0.80-$0.82, resistance $0.87-$0.96. Volume 3.6K-690K vs 703K avg.
๐ง *Fundamentals*: FDA-cleared 3D ECG platform, 16-17 employees. Pre-revenue, -$21M annual loss, EPS -$0.56 to -$0.62. 8 analysts: 1 sell, 2 hold, 5 buy = "Moderate Buy".
Bottom line: Tech de-risked with FDA nods + peer review, commercial launch underway. But heavy cash burn, stock beaten down. Hold $0.80 or $0.54 retest. Need $1.00-$1.20 break for trend change.
Spec medtech turnaround or wait for revenue traction?
$BEAT
#OpenAIConfidentialIPOFiling #SaharaAIDrops55PercentIn15Minutes #SBFSeeksPresidentialPardonFTTJumpsOver50Percent #Over200CryptoGroupsUrgeSenateCLARITYActVote #BinanceAlphaKGENAirdropRound2Live
*HeartBeam (BEAT) flat +0.12% to +0.92% at $0.81-$0.82, trying to base above $0.80 support.*
Price: *$0.81-$0.84* | Market cap: *$46.6M-$50.3M* | 52-week range: *$0.54-$4.00*
๐ *Move*: +0.12% to +0.92% today. Down -3.4% yesterday, -6.7% past 5 days, -65.7% YTD. Still -79% from $4.00 high. Analyst avg target $4.33 implies +433% upside.
๐ท๏ธ *Catalyst*: Q1 2026 results: $4.7M net loss but began first US commercial partnerships + raised $11.5M in April. New JACC peer-reviewed study shows portable ECG can identify heart attack risk at home vs 12-lead. Zacks upgraded to Buy #2.
โ ๏ธ *Technicals*: Trading below all MAs: 5-day $0.87, 20-day $0.91, 200-day $1.46. RSI 38-39 = oversold. Key support $0.80-$0.82, resistance $0.87-$0.96. Volume 3.6K-690K vs 703K avg.
๐ง *Fundamentals*: FDA-cleared 3D ECG platform, 16-17 employees. Pre-revenue, -$21M annual loss, EPS -$0.56 to -$0.62. 8 analysts: 1 sell, 2 hold, 5 buy = "Moderate Buy".
Bottom line: Tech de-risked with FDA nods + peer review, commercial launch underway. But heavy cash burn, stock beaten down. Hold $0.80 or $0.54 retest. Need $1.00-$1.20 break for trend change.
Spec medtech turnaround or wait for revenue traction?
$BEAT
#OpenAIConfidentialIPOFiling #SaharaAIDrops55PercentIn15Minutes #SBFSeeksPresidentialPardonFTTJumpsOver50Percent #Over200CryptoGroupsUrgeSenateCLARITYActVote #BinanceAlphaKGENAirdropRound2Live